TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00662116
Drug: alagebrium
Normalized name: Alagebrium
DrugBank: Alagebrium (DB12497)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg (two 100 mg tablets) two times daily for 24 weeks
Study: NCT00825812
Drug: Sugammadex
Normalized name: Sugammadex
DrugBank: Sugammadex (DB06206)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: After induction of anesthesia an intubation dose of 0.6 mg/kg rocuronium was administered. Maintenance doses of 0.1-0.2 mg/kg rocuronium intravenous (IV) could be administered if necessary. At reappearance of T2 after the last administration of rocuronium, an IV single bolus dose of 2.0 mg/kg sugammadex was administered.
Study: NCT02165891
Drug: insertion of a chest drain with urokinase instillation
DrugBank: Urokinase (DB00013)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Other interventions except drainage procedure are the same in both arms
Study: NCT01107626
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT01107626
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01107626
Drug: Pemetrexed Disodium Heptahydrate
Normalized name: PEMETREXED DISODIUM HEPTAHYDRATE
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given IV
Study: NCT00309556
Drug: Epirubicin
Normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6 cycles 75mg/m2 i.v. day 1 q3w
Study: NCT00309556
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6 cycles 75mg/m2 i.v. day 1 q3w
Study: NCT00309556
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: cycle 1: 8mg/kg i.v. day 1 cycle 2-6: 6mg/kg i.v. day 1 (=6 cycles q3w)
Study: NCT00825812
Drug: neostigmine
Normalized name: Neostigmine
DrugBank: Neostigmine (DB01400)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After induction of anesthesia an intubation dose of 0.6 mg/kg rocuronium was administered. Maintenance doses of 0.1-0.2 mg/kg rocuronium IV could be administered if necessary. At reappearance of T2 after the last administration of rocuronium, an IV single bolus dose of 50 µg/kg neostigmine (combined with 10-20 μg.kg-1 atropine, in a ratio ranging from 2.5:1 to 5:1) was administered.
Study: NCT00171574
Drug: Valsartan
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00171574
Drug: Valsartan plus HCTZ
Normalized name: hydrochlorothiazide / valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00171574
Drug: Lisinopril
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02183636
Drug: Linagliptin/pioglitazone, FDC formulation C5
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: film coated tablet (5 mg/45 mg)
Study: NCT02183636
Drug: Linagliptin/pioglitazone, FDC formulation C8
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: film coated tablet (5 mg/45 mg)
Study: NCT02183636
Drug: Linagliptin tablet
Normalized name: Linagliptin Tablets
DrugBank: Linagliptin (DB08882)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5 mg
Study: NCT02183636
Drug: pioglitazone tablet (Actos®)
Normalized name: pioglitazone Oral Tablet [Actos]
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 45 mg
Study: NCT03136263
Drug: Oxytocin nasal spray
Normalized name: oxytocin Nasal Spray
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose intranasal oxytocin (24 IU; Syntocinon® nasal spray, Victoria Pharmacy, Zürich, Switzerland)
Study: NCT02560012
Drug: Sunitinib
Normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: One 50-mg capsule taken orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off
Study: NCT02560012
Drug: Temsirolimus
Normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 25 mg by an IV infusion over 30-60 minutes, once a week
Study: NCT02560012
Drug: Sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 mg (2 tablets) orally twice daily without food
Study: NCT02560012
Drug: Pazopanib
Normalized name: Pazopanib
DrugBank: Pazopanib (DB06589)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 800 mg orally once a day without food, at least 1 hour before or 2 hours after a meal
Study: NCT02560012
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 10 mg orally once daily with or without food
Study: NCT02560012
Drug: Axitinib
Normalized name: Axitinib
DrugBank: Axitinib (DB06626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mg orally twice daily
Study: NCT02923128
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine 3 ug/kg is diluted to 150ml with 0.9% saline,continuous micro-pump infusion for 72 hours with 2ml/h speed.
Study: NCT04085627
Drug: Valsartan and Amlodipine Tablets
Normalized name: valsartan and amlodipine
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1 tablet contains Valsartan 80mg\& Amlodipine 5mg
Study: NCT02923128
Drug: Sufentanyl
Normalized name: Sufentanyl
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sufentanyl 3 ug/kg is diluted to 150ml with 0.9% saline,continuous micro-pump infusion for 72 hours with 2ml/h speed.
Study: NCT02923128
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline is used to dilute other drugs
Study: NCT00102414
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01644773
Drug: Crizotinib
Normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Starting dose level:~* Initial Treatment Plan: 130 mg/m\^2 per dose~* Modified Treatment Plan per Amendment 1.0: 165 mg/m\^2 per dose~The dose of a single agent will be increased by approximately 30% in each subsequent cohort until the MTD of this combination is reached.~The doses of each agent will not exceed their single-agent MTD already determined for children with recurrent solid tumors.~Cycle 1 (28 days): once a day for 28 days~Cycles 2-26 (28 days each): once a day
Study: NCT01644773
Drug: Dasatinib
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Starting dose level: 50 mg/m\^2 per dose~The dose of a single agent will be increased by approximately 30% in each subsequent cohort until the MTD of this combination is reached.~The doses of each agent will not exceed their single-agent MTD already determined for children with recurrent solid tumors.~Cycle 1 (28 days): starting on day 3, once a day for 28 days~Cycles 2-26 (28 days each): once a day
Study: NCT02442713
Drug: fluvoxamine
Normalized name: Fluvoxamine
DrugBank: Fluvoxamine (DB00176)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: fluvoxamine: 50-300mg/day
Study: NCT01996085
Drug: lisinopril
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Angiotensin converting enzyme inhibitor recommended in case of:~1. hyperconstrictive profile (SVRI \> 2500-2800 dyn•s•cm-5•m2)~2. hyperdynamic profile (CI \> 4.2 l/min/m2 and/or HR \> 80/min) and office SBP ≥ 160 mm Hg and/or DBP ≥ 100 mmHg and/or 24-h mean SBP ≥ 140 mm Hg and/or 24-h mean DBP ≥ 90 mm Hg (in combination with nebivolol)~3. hypervolemic profile (man - TFC \> 34 1/kOhm; women - TFC \> 24 1/kOhm) and office SBP ≥ 160 mm Hg and/or DBP ≥ 100 mmHg and/or 24-h mean SBP ≥ 140 mm Hg and/or 24-h mean DBP ≥ 90 mm Hg (in combination with diuretic)~4. balanced profile
Study: NCT01996085
Drug: Telmisartan
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Angiotensin receptor blocker recommended in terms as for lisinopril in case of its intolerance (e.i. cough)
Study: NCT01996085
Drug: Nebivolol
Normalized name: Nebivolol
DrugBank: Nebivolol (DB04861)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Beta-blocker recommended in case of:~1.hyperdynamic profile (CI \> 4.2 l/min/m2 and/or HR \> 80/min)
Study: NCT01996085
Drug: Amlodipine
Normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1/ SVRI \> 2800 dyn•s•cm-5•m2 (in combination with lisinopril/telmisartan)
Study: NCT01996085
Drug: lisinopril
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug choice at the discretion of physician (blinded to ICG)
Study: NCT01996085
Drug: Telmisartan
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Angiotensin receptor blocker recommended as for lisinopril in case of its intolerance (e.i. cough)
Study: NCT01996085
Drug: Nebivolol
Normalized name: Nebivolol
DrugBank: Nebivolol (DB04861)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug choice at the discretion of physician (blinded to ICG)
Study: NCT01996085
Drug: Amlodipine
Normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug choice at the discretion of physician (blinded to ICG)
Study: NCT02720406
Drug: Intravenous ketamine0.5mg/kg
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ketamine 0.5mg/kg after anesthesia and before surgery.
Study: NCT02720406
Drug: Nebulized Ketamine 1mg/kg
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulized Ketamine 1mg/kg given by nebulizer before anesthesia.
Study: NCT02720406
Drug: Nebulized Ketamine 2mg/kg
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulized Ketamine 2mg/kg given by nebulizer before anesthesia.
Study: NCT01270087
Drug: Adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 40 mg IV every 14 days
Study: NCT00145002
Drug: VCAP-AMP-VECP with G-CSF and intrathecal prophylaxis
Normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00145002
Drug: biweekly-CHOP with G-CSF and intrathecal prophylaxis
Normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT04182672
Drug: FX006
Normalized name: Triamcinolone Acetonide Extended-Release
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will be injected with the 5mL of FX006. This injection may be followed with up to 3mL of ropivacaine (depending on the capacity of the bursa), under ultrasound guidance.
Study: NCT01971385
Drug: Squaric Acid solution
DrugBank: Squaric acid dibutyl ester (DB12223)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01810718
Drug: nilotinib
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maximum tolerated dosage (MTD) will be defined in Phase I. First 3 patients (pts) will receive Nilotinib 200mg daily dose. If no dose limiting toxicities after at least 1month the next 3 pts will be treated with 300mg. If are\>=2 dose limiting toxicities the Phase I will end and MTD will be defined as the next lower dosage. If they will observe 1dose limiting toxicities, they will treat other 3 pts (same dosage); if there isn't dose limiting toxicity, they will increase the dosage in the next cohort; but if they will observe another dose limiting toxicity (tot limiting toxicities 2/6 pts), the study will continue using the previous dose. MTD will be considered the maximum dosage used to treat 6 pts achieving at most 1 dose limiting toxicities, or the previous dosage if with this dosage they we will achieve 2 dose limiting toxicities. Doses will not be escalated beyond \>600 or \<200mg/die The MTD will be used for phase II
Study: NCT00387491
Drug: MOA-728
Normalized name: Moab, chimeric, SGN-30, to CD30 antigen
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00332228
Drug: depot naltrexone
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: long-acting depot parenteral formulation of naltrexone
Study: NCT00332228
Drug: BNT
Normalized name: BNT111
DrugBank: BNT111 (DB18177)
Approvals — FDA: no, EMA: no, PMDA: no
Description: behavioral therapy with oral naltrexone maintenance for the treatment of heroin addiction
Study: NCT01088399
Drug: Somatropin (rDNA origin)
Normalized name: Somatropin (rDNA origin)
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose, frequency and duration are at discretion of attending physician, and determined on an individual basis.
Study: NCT02397057
Drug: Injectafer
Normalized name: Injectafer
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01546688
Drug: Zonisamide at targeted daily doses of 100-500 mg/day
DrugBank: Zonisamide (DB00909)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Each group received 2 doses a day (in the morning and evening) during the Titration Period, once a day (in the evening) or BID during the Maintenance Phase, comprising 25 mg, 50 mg, or 100 mg of ZNS capsules
Study: NCT01178203
Drug: Tramadol
Normalized name: Tramadol
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tab, 100mg in 6, 12 and 24 hours after root canal treatment
Study: NCT01178203
Drug: Novafen
Normalized name: Novaferon
DrugBank: Novaferon (DB16483)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 325 mg in 6, 12 and 24 hours after root canal treatment
Study: NCT03120715
Drug: estrogen
Normalized name: Estrogen
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The oral estrogen replacement is 4mg per day (2 mg twice daily), 4 days; 6 mg per day, 4 days. Then, the patient's endometrial thickness is evaluated through vaginal ultrasound and if the endometrial thickness is \<7 mm, increasing estrogen by 2 mg is given to patients until the endometrial thickness is \>9 mm.
Study: NCT03120715
Drug: hCG
Normalized name: HCG
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: If the endometrial thickness is greater than 9 mm, Human Chorionic Gonadotropin（hCG） 10000 IU will be administered via intramuscular injection.
Study: NCT03120715
Drug: progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: on the next day(D0), progesterone in oil 60 mg will be administered via intramuscular injection. Transfer of thawed embryos will be performed 3 days later(D3).
Study: NCT03543137
Drug: Nicotine Prototype Mini lozenge
Normalized name: nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A single dose of a prototype nicotine 4mg lozenge will be placed in participants mouth, occasionally moving it side to side. Allowing it to slowly dissolve and try to minimize swallowing. Participants will be instructed not to chew lozenge. The lozenge should be completely dissolved.
Study: NCT01366287
Drug: PF-03882845
Normalized name: PF-03882845
DrugBank: PF-03882845 (DB11814)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg of PF-03882845 suspension (75% SDD) will be given as a single oral dose under fasted condition
Study: NCT01366287
Drug: PF-03882845
Normalized name: PF-03882845
DrugBank: PF-03882845 (DB11814)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg PF-03882845 Tablet (75% SDD) will be given as a single oral dose under fasted condition
Study: NCT01366287
Drug: PF-03882845
Normalized name: PF-03882845
DrugBank: PF-03882845 (DB11814)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg PF-03882845 Tablet (75% SDD) will be given as a single oral dose under fed condition
Study: NCT04027322
Drug: Budesonide 0.25 MG/ML Inhalant Solution
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Both medications used for the intervention groups are Glucocorticoids. The effect of glucocorticoids in AP can be attributed to their anti-inflammatory actions. They inhabit the formation of the pro-inflammatory mediators in the endothelial cells of the airways. This will decreases the inflammatory reaction at the pharynges which result in a reduction of throat pain.~Studies have shown that the use of a single dose of systemic glucocorticoids for acute pharyngitis did not result in significant adverse events and no serious adverse events were reported (7) (8).
Study: NCT00699686
Drug: Glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daily bedtime subcutaneous insulin Glargine in individualized doses.
Study: NCT04027322
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Both medications used for the intervention groups are Glucocorticoids. The effect of glucocorticoids in AP can be attributed to their anti-inflammatory actions. They inhabit the formation of the pro-inflammatory mediators in the endothelial cells of the airways. This will decreases the inflammatory reaction at the pharynges which result in a reduction of throat pain.~Studies have shown that the use of a single dose of systemic glucocorticoids for acute pharyngitis did not result in significant adverse events and no serious adverse events were reported (7) (8).
Study: NCT00699686
Drug: Detemir
Normalized name: Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Daily bedtime subcutaneous insulin Detemir in individualized doses.
Study: NCT03780790
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: % 0,25
Study: NCT00349778
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100 mg etoposide as 5 mL solution in clear ampules for injection.
Study: NCT00349778
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Melphalan as single-use glass vials of freeze-dried melphalan hydrochloride (equivalent to 50 mg of melphalan), to be reconstituted in 0.9% sodium chloride solution to not greater than 0.45 mg/mL, and administered within 1 hour of constitution.
Study: NCT00349778
Drug: Carmustine
Normalized name: Carmustine
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carmustine as a powder for reconstitution in 100 mg vials, to be reconstituted with 3 mL sterile dehydrated ethanol and D5W. Carmustine should be dissolved in 500 mL of 5% dextrose in water (D5W) and infused IV over 2 hours.
Study: NCT00349778
Drug: Filgrastim
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Filgrastim in vials of 300 µg or 480 µg at a concentration of 300 µg/mL, to be given as a daily subcutaneous injection.
Study: NCT01775605
Drug: Synera
Normalized name: Synera
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synera Pain Patch
Study: NCT03311789
Drug: PD-1 inhibitor + Gemcitabine + Cisplatin
Normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine: 1000mg/m2 on day 1 and 5 every 3 weeks. Cisplatin: 75mg/m2 on day 1 every 3 weeks. PD-1 inhibitor: Nivolumab 3mg/kg, or SHR-1210 200mg.
Study: NCT00480246
Drug: BL 1020
Normalized name: BL-1020
DrugBank: BL-1020 (DB05687)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00480246
Drug: Perphenazine
Normalized name: Perphenazine
DrugBank: Perphenazine (DB00850)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04624490
Drug: Hyperpolarized Xe129
Normalized name: xenon-129, hyperpolarized
DrugBank: Xenon (DB13453)
Approvals — FDA: no, EMA: no, PMDA: no
Description: During MRI scanning, subject will inhale hyperpolarized xenon gas for a maximum of 16 seconds per scan, with a maximum of 4 MR scans + Calibration in a given imaging session.
Study: NCT04307082
Drug: [14C]-Ibrexafungerp
DrugBank: Ibrexafungerp (DB12471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radio-labeled Ibrexafungerp, single dose.
Study: NCT01822977
Drug: omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00639626
Drug: insulin detemir [rDNA origin] injection
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Starting dose of 0.1-0.3 units/kg/day in a once daily subcutaneous injection.
Study: NCT03484520
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: tablet, oral
Study: NCT03484520
Drug: Dinaciclib
Normalized name: Dinaciclib
DrugBank: Dinaciclib (DB12021)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous
Study: NCT01605110
Drug: Hyperbaric oxygen treatment
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients that volunteer to participate in this study will be exposed to two treatments (one before surgery; one after surgery) of 100% oxygen at 2.0 atmospheres absolute (ATA) inside mono-place chambers for 90 minutes (at depth).
Study: NCT03209011
Drug: Peginterferon Alfa-2a
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients untreated in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly in experiment group.
Study: NCT01605110
Drug: Air sham
Normalized name: Herbal Essences Argan Oil Repair Shampoo
DrugBank: Argan oil (DB14310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients that volunteer to participate in this study will be exposed to two treatments (one before surgery; one after surgery) of medical grade air (21%oxygen; sham) at 1.2 ATA inside mono-place chambers for 90 minutes.
Study: NCT00277108
Drug: Escitalopram (Lexapro)
Normalized name: escitalopram Oral Tablet [Lexapro]
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00367835
Drug: SPD503 (Guanfacine hydrochloride)
Normalized name: Guanfacine Hydrochloride
DrugBank: Guanfacine (DB01018)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects will start at 1mg tablet each morning and will subsequently be titrated (in 1 mg weekly increments) to optimal dose based upon tolerance and response to investigational product (not to exceed 4 mg/day).
Study: NCT01640444
Drug: FOLFIRI + bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: * Bevacizumab 5 mg/kg iv, followed by~* Irinotecan 180 mg/m2 iv administered over a period of 30-90 minutes, followed by~* Leucovorin (LV) 400 mg/m2 iv administered over a period of 2 hours, followed by~* 5-FU 400 mg/m2 iv bolus, followed by~* 5-FU 2,400 mg/m2 for 46 h continuous infusion. This treatment will start on day 1 and will be repeated every 2 weeks (1 cycle).